丹麦专利DK201600113U1 Transdermal therapeutic system for the administration of rivastigmine

专利PDF首页>>丹麦专利

专利附录

专利说明

权利要求

类似技术

同族专利

引用文献

法律状态

优先权

专利摘要:
The invention relates to rivastigmine as a free base or in the form of a pharmaceutically acceptable salt for use in a method of preventing, treating or delaying the development of dementia or Alzheimer's disease, wherein rivastigmine is administered in a Transdermal Therapeutic System and the starting dose is greater than 3 mg. rivastigmine per day.
公开号:DK201600113U1
申请号:DK201600113U
申请日:2016-10-07
公开日:2017-01-13
发明作者:Paul M Gargiulo；Roger Michael Lane；Beatrix Platt；Frank Theobald；Bettina Wall
申请人:Novartis Ag；Lts Lohmann Therapie Systeme Ag；
IPC主号:

专利说明:

The present invention relates to rivastigmine as a free base or in the form of a pharmaceutically acceptable salt, for use in a method of preventing, treating or delaying the development of dementia or Alzheimer's disease, wherein rivastigmine is administered in a Transdermal Therapeutic System and wherein the starting dose is as defined. in claim 1.
Background to the creation
Transdermal therapeutic systems (TTSs) and their preparation are well known in the art. EP 1047409 discloses a TTS containing rivastigmine and an antioxidant. GB 2203040 discloses a TTS containing rivastigmine and a hydrophilic polymer.
These TTSs have valuable properties. However, there is a need for additional TTSs with improved features. In particular, there is a need to provide TTSs to improve compliance, adherence, tolerability and / or security. DE 19918106A1 discloses a TTS comprising at least one pharmaceutically active substance and a neutralized acid polyacrylate pressure sensitive adhesive wherein rivastigmine is referred to as a suitable pharmaceutically active substance.
Tse Francis L. S. et al., Pharmaceutical Research, Vol. 15, no. 10 (1998), pages 1614-1620 discuss transdermal, oral and intravenous administration of rivastigmine to pigs. Thus, it is an object of the present invention to provide a TTS with improved compliance, adhesion, tolerability and / or safety properties.
It is a further object of the present invention to provide a TTS with a relatively large amount of active substance which has an adhesive strength to ensure safe application throughout the application period.
It is a further object of the present invention to provide a TTS with a relatively large amount of active substance without having an inappropriately large area.
It is a further object of the present invention to provide a TTS with improved adhesive properties without altering the release profile of the active substance.
It is a further object of the present invention to provide a controlled release treatment method and compositions that substantially improve the efficacy and tolerability of rivastigmine.
It is a further object of the present invention to provide a controlled release treatment method and compositions substantially reducing the time and resources necessary to administer rivastigmine to obtain a therapeutic benefit.
It is a further object of the present invention to provide a controlled release treatment method and compositions that substantially improve compliance with rivastigmine treatment.
It is a further object of the present invention to provide a controlled release treatment method and compositions having substantially less inter-individual variation in the plasma concentrations of rivastigmine necessary to produce a therapeutic benefit without unacceptable side effects.
This is achieved by a TTS as defined in the appended claim.
Summary of the production
Embodiments of the present invention are apparent from the related independent claim. In one aspect, the present invention relates to rivastigmine as a free base or in the form of a pharmaceutically acceptable salt for use in a method of preventing, treating or delaying the development of dementia or Alzheimer's disease, wherein rivastigmine is administered in a TTS and wherein the starting dose is as defined in claim 1.
FIG. Figure 1 shows a bar graph illustrating the different adhesive strengths of a TTS with an additional silicone adhesive layer (TTS # 2) and a TTS without any additional silicone adhesive layer (TTS # 1).
FIG. Figure 2 shows a diagram illustrating the different permeation rates of rivastigmine through full thickness human skin administered by a TTS with an additional silicone adhesive layer (TTS # 2) or a TTS without any additional silicone adhesive layer (TTS # 1) .
FIG. Figure 3 shows a diagram illustrating the different permeation rates of rivastigmine through an EVA membrane administered by a TTS with an additional silicone adhesive layer (TTS # 2) or a TTS without any additional silicone adhesive layer (TTS # 1).
FIG. Figure 4 shows a diagram illustrating plasma PK profiles after capsule administration (above) or TTS # 2 (below).
Experiments with active substances for the treatment of Alzheimer's disease have surprisingly shown that a line of silicone adhesive can be applied to a poorly adhered reservoir matrix and thus substantially increase the adhesive properties of the composition without damaging the thermodynamic properties of the TTS, ie. without reducing the release of active substance from the matrix and its permeation through the skin.
The results of the transdermal application of active substances for the treatment of Alzheimer's disease by the applicant can of course be transferred to other groups of active substances. Therefore, it can generally be stated that an increasing proportion of active substance in the TTS adhesive polymer matrix for many active substances significantly reduces the adhesive properties of the TTS if the active substances are solid at room temperature. If the active substances are in liquid state at room temperature, large amounts of so-called '' thickening polymers '' (e.g., cellulose or polyacrylate derivatives) must usually be added to achieve mechanical processability of the polymers, which also leads to a reduction of the adhesive properties. In one embodiment, the present disclosure provides TTSs comprising a backing layer, a reservoir containing at least one active substance and a polymer, an adhesive layer comprising a silicone polymer and a tackifier.
A TTS according to the specification exhibits improved adhesive properties. Furthermore, the TTS thus obtained has very surprisingly substantially the same release profile when compared with a standard TTS.
The present invention further relates to substantial improvement in the efficacy and tolerability of rivastigmine by the application of a TTS in the range of 2 to 50 cm 2, the composition providing an average maximum plasma concentration of about 10%. 1 to 30 ng / ml from an average of approx. 2 to 16 hours after application and an AUC24h of approx. 25 to 450 ng-h / ml after repeated "QD" administration (ie once daily).
A TTS as used in the preparation shows, quite surprisingly, improved tolerability, especially with respect to gastrointestinal adverse events, such as nausea and vomiting, relative to equivalent dose levels (AUC24h) of the Exelon® capsule.
Unless otherwise indicated, the terms used in this generation have the following meanings:
The term "transdermal therapeutic system" means any device capable of releasing a pharmaceutically active substance through the skin. This especially includes self-adhesive devices such as patches.
The term '' backing layer '' means the layer that is distant from the skin. This layer is preferably impermeable to active substance. Any suitable material or combination of materials may be used. Eg. For example, polyethylene terephthalate (PET), polyethylene, polypropylene, polyurethane, etc. can be used.
The term "reservoir" means a layer containing one or more active substances in association with one or more polymers. In a preferred embodiment, the reservoir comprises an active substance in the form of a polymer matrix.
The term "adhesive layer" refers to the layer facing the skin. This layer comprises a silicone polymer and an adhesive.
The term '' removable protective layer '' means the layer that is removed from the patch before it is applied to the skin. This layer is preferably impermeable to the active substance. Any suitable material or combination of materials may be used.
For example, silicone-treated PET, silicone-treated polypropylene, silicone-treated polyethylene, fluoropolymer-coated PET, fluoropolymer-coated polypropylene, fluoropolymer-coated polyethylene, etc. can be used.
The term "polymer", when used in conjunction with the active substance reservoir, means a polymer selected from the group consisting of polydimethylsiloxanes, polyacrylates, polyisobutylene, polybutylenes, and styrene-isoprene-styrene block copolymers or mixtures thereof, especially in combination with resins .
Preferred polymers to be used in the reservoir are selected from the group consisting of polyacrylates, e.g. Durotak 2353 from National Starch.
The term '' silicone polymer '' means polymers based on polydimethylsiloxane, e.g. the Dow Corning Amine Compatible Bio-PSA Q7-4302.
The term "tackifier" refers to a substance which increases the adhesion / stickiness of the transdermal preparation. Preferred adhesives are selected from the group consisting of silicone oils, glycerol esters of hydrogenated resin acids, hydroabietyl alcohols, hydrogenated esters, hydrogenated esters, hydrogenated esters, hydrogenated esters, of partially hydrogenated wood rosin, rosin esters, etc., and combinations thereof, as appreciated by one of ordinary skill in the art, TTSs are made of several layers with particular properties, which may vary with respect to the individual composition and thickness of the individual layers. In a preferred embodiment of the present invention, the TTS comprises an adhesive layer comprising a silicone polymer and a tackifier and the active substances used have a low saturation solubility in the silicone adhesive, such as the saturation solubility of the active substance in the silicone adhesive. than 15% by weight, preferably preferably less than 10% by weight and especially between 2 and 8% by weight. In embodiments of the present invention wherein the TTS comprises an adhesive layer comprising a silicone polymer and a tackifier, the silicone adhesive layer preferably does not reduce the permeation of the active substance from the reservoir through the skin, more preferably not more than 20% and especially not more than 10%. In embodiments of the present invention wherein the TTS comprises an adhesive layer comprising a silicone polymer and a tackifier, the surface weight of the silicone adhesive layer is e.g. in the range 5 to 60 g / m2, especially in the range 10 to 30 g / m2.
The composition used in the preparation can be used to administer widely different active agents. Suitable active substances are those identified above. In a preferred embodiment, the TTS comprises a reservoir and the reservoir further comprises adjuvants such as fillers, antioxidants, dyes, skin penetration promoters and / or preservatives. Such auxiliaries are well known to those skilled in the art and may be selected from standard works, see in particular Fiedler's '' Lexicon der Hilfstoffe '', 4th edition, ECV Aulendorf 1996 and '' Handbook of Pharmaceutical Excipients '' Wade and Weller Ed. (1994), the contents of which are incorporated herein by reference. In a particularly preferred embodiment, the TTS comprises a reservoir and the reservoir contains an antioxidant such as α-tocopherol, ascorbyl palmitate or butylated hydroxytoluene (BHT). In a preferred embodiment, the TTS comprises a reservoir and the reservoir contains a skin penetration promoter such as transcutol, glycerol, glycerol esters, fatty acids, fatty acids salts, azone, diethyltoluamide, propylene glycol, propylene glycol esters, butanediol, isopropyl esters, urea, etc. It comprises a reservoir and an adhesive layer, the thickness ratio of the reservoir to the adhesive layer is between 5: 1 and 1: 2, preferably between 2: 1 and 1: 1. In a preferred embodiment, the TTS has an adhesive strength> 5 N / 10 cm 2, preferably> 10 N / 10 cm 2. In a preferred embodiment, the TTS has an adhesive strength <100 N / 10 cm 2, preferably <50 N / 10 cm 2. The adhesive strength is determined according to standard methods, e.g. as described in the Examples. In a preferred embodiment, the TTS has a size range from 2 to 50 cm 2, especially 5 to 20 cm 2. In a preferred embodiment, the TTS provides an average maximum plasma concentration of rivastigmine of 1 to 30 ng / ml from an average of 2 to 16 hours after application with an AUC24h of 25 to 450 ng-h / ml, and in particular provides the TTS. an average maximum plasma concentration of rivastigmine of 2.5 to 20 ng / ml from a mean of 4 to 12 hours after application with an AUC24h of 45 to 340 ng-h / ml. In a further embodiment wherein the TTS comprises an adhesive layer comprising a silicone polymer and a tackifier and a reservoir comprising an active substance in the form of a polymer matrix, not only the polymer matrix contains the active substances but also the silicone adhesive layer. In a further aspect, the preparation provides free base rivastigmine or in the form of a pharmaceutically acceptable salt for use in preventing, treating or delaying the course of dementia wherein the rivastigmine is administered in a TTS and the starting dose is as defined in claim 1. In a further aspect provides the rivastigmine for use in a method of preventing, treating, or delaying the course of dementia in Parkinson's disease wherein the rivastigmine is administered in a TTS and the starting dose is as defined in claim 1. In a further aspect, the rivastigmine provides for use in a method. for the prevention, treatment or delay of the progression of Alzheimer's disease wherein the rivastigmine is administered in a TTS and the starting dose is as defined in claim 1.
The preparation of a TTS according to the invention may be carried out by any method known to those skilled in the art.
Suitably, a method for preparing the TTS used in the present invention comprises the following steps: a) preparing an adhesive solution containing the active substance, b) applying the adhesive solution containing the active substance, c) drying the adhesive solution containing the active substance, d (e) application of the silicone adhesive solution; (f) laminating the adhesive solution containing the active substance with the silicone adhesive solution; (g) punching and placing in a pocket.
About the biopharmaceutical properties of rivastigmine in humans has been little published in detail. It is absorbed quickly and completely. We have found that it is metabolized mainly by hydrolysis with esterases, e.g. acetyl and butyryl cholinesterase, and has a plasma half-life of 1 hour. It is subject to pre-systemic and systemic metabolism. We have now found that a TTS containing rivastigmine can be produced with beneficial properties, e.g. better tolerability.
The production further provides a TTS containing as active ingredient rivastigmine with an AUC24h of approx. 25 to 450 ng * h / ml after repeated QD administration (ie once daily).
One skilled in the art will be familiar with how a TTS with the plasma profiles defined above is to be prepared. One skilled in the art would appreciate that such plasma profiles can be obtained by varying, for example: • the composition of the first and / or the second component, e.g. the nature and amount of excipients and / or active substances, • the type of adhesive layer, • the dimension of the patch.
A TTS can be formulated for the following aspects: • the time until the release of the active substance (retention time), • the rate of release of the active substance (fast or slow), • the duration of release of the active substance (long or short), • reduction. of first-pass metabolism; • improvement of patient compliance; • reduction of application intervals. Such aspects can be observed in standard in vitro dissolution experiments, e.g. in water or, if desired, in body fluids, e.g. artificial stomach juice.
About reliable, time-controlled release preparations that allow for the predetermined release of single or repeated doses of active substances have been little published. There is a need for such compositions which are commercially acceptable.
After extensive testing, we have now found that it is possible to produce a TTS capable of a specific time, ie. with a time delay or delay, to release a pharmaceutically active agent or mixture of active agents, e.g. substantially independent of the concentration and type of ions present in the gastrointestinal environment, e.g. hydrogen ions and hydroxyl ions, i.e. independently of pH, phosphate ions and also independent of enzymes found in the surrounding body fluid.
The exact amounts of doses of active substances and of the TTS to be administered depend on a number of factors, e.g. the condition to be treated, the desired duration of treatment, and the rate of release of the active agent.
For example, the amount of active agent required and its rate of release may be determined by known techniques in vitro or in vivo by determining how long the concentration of a particular active agent in the blood plasma remains at an acceptable level for a therapeutic effect. The TTS used in the generation, e.g. the preparation of once-daily drug forms for patients who may take more than one dose of one active agent per day. day, e.g. at specific times so that their treatment is simplified. With such compositions, the tolerability of tear stigma can be improved and this may allow a higher starting dose and a reduced number of dose titration steps.
An increased tolerability of rivastigmine in the compositions can be observed in standard animal studies and in clinical trials. The following non-limiting examples illustrate the creation:
Example
I. Preparation of TTS The following experimental examples were carried out using the cholinesterase inhibitor rivastigmine as its free base. For the experiments, two TTSs were prepared: TTS # 1: Substrate parts having a surface weight of 60 g / m2 having the following composition were prepared:
Rivastigmine (free base) 30.0% by weight
Durotak® 387-2353 (polyacrylate adhesive) 49.9% by weight
Plastoid® (acrylate copolymer) 20.0% by weight
Vitamin E 0.1% by weight TTS No. 2: Substrate parts were prepared in the form of a two-layer preparation, one layer of the two-layer preparation corresponding to TTS No. 1. The said layer is provided with a silicone adhesive layer having a surface weight of 30 g / m2 in accordance with having the following composition:
Bio-PSA® Q7-4302 (silicone adhesive) 98.9% by weight
Silicone Oil 1.0% by weight
Vitamin E 0.1% by weight The saturation solubility of rivastigmine in the form of its free base in the silicone adhesive is approx. 5% by weight. II. Determination of adhesive strength
The adhesive strength of both TTSs was determined by methods known to those skilled in the art, taking into account the following details: size of substrate parts: 10 cm2 sample plate: steel peel angle: 90 ° peel speed: 300 mm / min.
For the two TTSs, they were obtained in FIG. 1. The diagram of FIG. Figure 1 clearly shows that applying a silicone adhesive layer to the acrylate adhesive matrix significantly increases its adhesive strength.
Rivastigmine is in the form of its free base liquid at room temperature. Therefore, it was necessary to add a '' thickening polymer '' (Plastoid® B) when incorporating 30% by weight of active substance. Thus, a substrate of low adhesive strength was obtained. When an additional silicone adhesive layer was used, the adhesive strength was approx. five times the adhesive strength of a comparable TTS without additional silicone adhesive coating. III. permeation
To determine if the application of an additional silicone adhesive layer affects the release of the active substance, permeation of rivastigmine through full-thickness human skin and EVA membranes were tested for both TTSs. For the permeation experiments, the following conditions apply:
The full-thickness human skin and the EVA membrane were each introduced into a modified Franz diffusion cell. The diffusion area was 1.51 cm 2. Phosphate buffer (pH 5.5) with 0.1% sodium azide was used as the acceptor medium. Acceptorm ed in one had a volume of 9 ml. The test temperature was adjusted to 32 ° C by means of a water bath and thus corresponded to the surface temperature of human skin in vivo.
The entire acceptor medium was replaced with fresh acceptor solution after 8, 24, 32, 48, 56 and 72 hours to ensure perfect dissolution conditions throughout the experimental period.
The content of rivastigmine in the acceptor medium was determined by HPLC.
The result of the permeation experiments is shown graphically in FIG. 2 and 3.
The results illustrate that virtually no differences in permeation rates of rivastigmine in the form of its free base through human skin were observed between the two TTSs (Fig. 2). The small differences are probably due to the use of a biological material such as skin and can be explained by local skin variations such as micro-lesions or hair follicles.
To eliminate variations caused by the use of biological material, the permeation experiments were repeated using an artificial membrane (EVA membrane). The 3 shows the results obtained with full thickness human skin, namely that the two TTSs do not differ in their permeation properties.
Surprisingly, application of the additional silicone adhesive layer has no effect on the permeation of the active substance through the skin.
According to the present description, therefore, TTSs with significantly higher adhesive strength can be produced while retaining their original size. IV. Pharmacokinetic properties
An open-label study with parallel groups for four periods of proportionally increasing dose was performed to assess 5 cm2, 10 cm2, 15 cm2 and 20 cm2 TTS Nos. 2 and 1.5 mg, 3 mg, 4.5 mg and 6 mg Exelon® capsules twice daily (BID) at steady state in patients with mild to moderate Alzheimer's disease.
Patients diagnosed with mild to moderate Alzheimer's disease were randomized to treatment with either TTS # 2 or capsules. The criteria for inclusion were: male or female (non-fertile) patients aged 50 to 85 who met the Alzheimer's type dementia (DSM-IV) criteria. Patients should be diagnosed with probable Alzheimer's disease in accordance with the NINCDS - ADRDA criteria with a MMSE rating of 10-26 (both inclusive) and no other medical conditions that could affect the study results. Based on previous experience in clinical trials, 14 days of titration were implemented for this study. At the time of this analysis, the following number of patients completed each of the four periods and were included in the pharmacokinetic assessment:
Capsule TTS No. 2 19 patients with dose 1.5 mg 2 x daily 18 patients with 5 cm2 dose 18 patients with dose 3.0 mg 2 x daily 18 patients with 10 cm2 dose 13 patients with dose 4.5 mg 2 x daily 16 patients with 15 cm2 dose 12 patients with 6.0 mg dose 2 x daily 11 patients with 20 cm2 dose
Rivastigmine pharmacokinetics were examined after both treatments on the last day of each titration period, except at the highest doses examined on the third titration day (so as not to miss plasma samples in case of early outcome due to poor tolerability). Plasma samples were analyzed for rivastigmine using LC-MS / MS with a lower quantification limit (LLOQ) of 0.2 ng / ml. Non-compartment standard pharmacokinetic parameters were derived from the individual plasma concentration / time profiles using WinNonlin Pro.
The pharmacokinetic parameters of rivastigmine are summarized in Table 1 (capsule therapy) and Table 2 (TTS treatment # 2). The mean plasma concentration versus time profiles (± SA) are shown in Figs. 4th
During the application of TTS # 2, a plateau concentration of rivastigmine was obtained at a median Wx of 8.0 hours for all TTS sizes. The uptake also increased proportionally with increasing doses, as shown in Table 3, but to a lesser extent than with the capsule, especially for AUC24h.
The inter-individual variation between individuals as judged by the coefficients of variation (CVs) for the uptake parameters of rivastigmine (C max and AUC24h) was generally lower after patch administration (CVs of 33-48%) compared to oral administration (CV 'is from 39-68%). V. Pharmacological Properties TTS # 2 exhibits improved pharmacological properties as compared to a capsule preparation as shown in a standard animal and clinical trial.
1 I 'ft ***} ,, 2 i vyyyv ^ Æ m «Ο ν I in ΙΛ *) m« r »·! ί ί ί Ά
Table 2. Descriptive statistics of pharmacokinetic parameters for rivastigmine after application of TTS # 2
o S Ώ rm £ mπ nafwrt Ηη <ΐϊ <^ ia = not available i
Table 3. Increase of rivastigmine uptake with increasing dose of rivastiamine Kaosel's TTS # 2

权利要求:
Claims (1)
[1]
1. Rivastigmine for use in a method of preventing, treating or delaying the development of dementia or Alzheimer's disease, wherein: rivastigmine is administered in a Transdermal Therapeutic System (TTS): the starting dose is as for a 5 cm 2 TTS containing rivastigmine in form of a dose of 9 mg applied in which one layer: has a surface weight of 60 g / m2 and the following composition: - rivastigmine (free base) 30.0% by weight - Durotak® 387-2353 (polyacrylate adhesive) 49, 9 wt% - Plastoid® B (acrylate copolymer) 20.0 wt% - vitamin E 0.1 wt% and wherein the above layer is applied to a silicone adhesive layer having a surface weight of 30 g / m 2 according to the following composition: - Bio-PSA® Q7- 4302 (silicone adhesive) 98.9 wt% - silicone oil 1.0 wt% vitamin E 0.1 wt% and an AUC24h of 25 to 450 ng * h / ml after repeated once daily administration.

类似技术:

公开号 | 公开日 | 专利标题

DK201600113Y4|2017-06-09|Transdermal therapeutic system for administration of rivastigmine

KR20130121139A|2013-11-05|Donepezil transdermal patch

TWI710381B|2020-11-21|Percutaneous absorption preparation

WO2008026381A1|2008-03-06|Nail patch

JP2007500711A|2007-01-18|Transdermal warfarin-containing delivery system

US20210251916A1|2021-08-19|Transdermal therapeutic system containing rivastigmine

MX2008006956A|2008-09-02|Transdermal therapeutic system

同族专利:

公开号 | 公开日

KR20170033449A|2017-03-24|

EP1959937A1|2008-08-27|

AR097045A2|2016-02-17|

EP3235495A1|2017-10-25|

MY162986A|2017-07-31|

HK1153646A1|2012-04-05|

JP5938612B2|2016-06-22|

PH12013500772A1|2016-01-18|

KR20210008440A|2021-01-21|

CA2563110A1|2007-06-01|

IL250734D0|2017-04-30|

SI2292219T1|2013-08-30|

JP2013177419A|2013-09-09|

IL191311A|2015-02-26|

DE14163637T1|2015-06-03|

ES2414455T3|2013-07-19|

AU2006320919A1|2007-06-07|

IL234364A|2016-06-30|

JP2009517468A|2009-04-30|

BR122013013162A2|2015-06-30|

CN101312717A|2008-11-26|

TWI389709B|2013-03-21|

ECSP088469A|2008-07-30|

PT2292219E|2013-06-24|

US20140134230A1|2014-05-15|

US20130266633A1|2013-10-10|

BRPI0619758A2|2011-10-18|

RU2450805C2|2012-05-20|

EP2286802A1|2011-02-23|

GT200800075A|2010-06-01|

DK201600113Y4|2017-06-09|

PL2292219T3|2013-09-30|

EP2292219B9|2015-02-18|

DK201300015Y4|2016-02-12|

DK201300059U1|2013-04-29|

RU2008126459A|2010-01-20|

DK2292219T3|2013-06-24|

KR20080071581A|2008-08-04|

EP2786748A1|2014-10-08|

MA30022B1|2008-12-01|

DK201300015U1|2013-02-08|

SG2014014989A|2014-06-27|

WO2007064407A1|2007-06-07|

AR057152A1|2007-11-21|

JP2016104737A|2016-06-09|

DK201300014U1|2013-02-08|

MY151020A|2014-03-31|

PL2292219T4|2014-03-31|

TW200732001A|2007-09-01|

KR20140072108A|2014-06-12|

IL234291A|2017-02-28|

EP2292219A1|2011-03-09|

DK201300014U3|2013-05-13|

NZ568273A|2011-06-30|

DK201300059U3|2013-05-13|

EP2292219B1|2013-06-12|

KR20180050441A|2018-05-14|

CN102048713A|2011-05-11|

AU2006320919B2|2011-04-28|

PH12013500771A1|2016-01-18|

ZA200803882B|2009-03-25|

KR20130143729A|2013-12-31|

TNSN08238A1|2009-10-30|

US20070128263A1|2007-06-07|

JP6298034B2|2018-03-20|

NO20082753L|2008-08-19|

AT11185U1|2010-06-15|

PH12013500772B1|2016-01-18|

DE202006021172U1|2013-05-07|

引用文献:

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

NL195004C|1987-03-04|2003-11-04|Novartis Ag|Pharmaceutical preparation containing phenyl carbamate.|

US5059426A|1989-03-22|1991-10-22|Cygnus Therapeutic Systems|Skin permeation enhancer compositions, and methods and transdermal systems associated therewith|

US5252335A|1989-07-12|1993-10-12|Cygnus Therapeutic Systems|Transdermal administration of lisuride|

DE4301783C1|1993-01-23|1994-02-03|Lohmann Therapie Syst Lts|Transdermal system per admin. of galanthamine - esp. for treatment of Alzheimer's disease and alcohol addiction|

US6316023B1|1998-01-12|2001-11-13|Novartis Ag|TTS containing an antioxidant|

GB9800526D0|1998-01-12|1998-03-11|Ciba Geigy Ag|Organic compounds|

DE19918106A1|1999-04-22|2000-10-26|Lohmann Therapie Syst Lts|Transdermal patches containing basic or neutral drug include adhesive acrylic acid polymer in alkali metal salt form|

DE19922662C1|1999-05-18|2000-12-28|Sanol Arznei Schwarz Gmbh|Transdermal therapeutic system containing tolterodine|

CN1240384C|1999-11-04|2006-02-08|美国爱科赛尔制药有限公司|Transdermal administration of huperzine|

US20020192243A1|1999-12-16|2002-12-19|Tsung-Min Hsu|Transdermal and topical administration of drugs for the treatment of Alzheimer's disease using basic enhancers|

US20030104041A1|1999-12-16|2003-06-05|Tsung-Min Hsu|Transdermal and topical administration of drugs using basic permeation enhancers|

DE10033853A1|2000-07-12|2002-01-31|Hexal Ag|Transdermal therapeutic system, containing highly dispersed silicon dioxide in matrix or adhesive layer to promote drug permeation through the skin|

AU3515502A|2000-12-05|2002-06-18|Noven Pharma|Crystallization inhibition of drugs in transdermal drug delivery systems and methods of use|

DE10103860B4|2001-01-30|2004-12-23|Lts Lohmann Therapie-Systeme Ag|Transdermal therapeutic system for the administration of carboxyl group-containing, non-steroidal anti-inflammatory drugs, and process for its preparation|

DE10159745A1|2001-12-05|2003-07-03|Lohmann Therapie Syst Lts|Transdermal therapeutic system with improved long-term comfort|

PT1509232E|2002-05-31|2009-01-07|Lundbeck & Co As H|A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer`s disease|

US20070166363A1|2004-02-19|2007-07-19|Lane Roger M|Use of cholinesterase inhibitors for treating vascular depression|

EP2596889B1|2011-11-23|2017-04-26|Sandvik Intellectual Property AB|A cutting insert and a milling tool|TWI389709B|2005-12-01|2013-03-21|Novartis Ag|Transdermal therapeutic system|

US9248104B2|2006-08-17|2016-02-02|Core Tech Solutions, Inc.|Transdermal methods and systems for treating Alzheimer's disease|

GB0823554D0|2008-12-24|2009-01-28|Novartis Ag|Process for the preparation of optically active compounds using transfer hydrogenation|

CN102803423A|2009-04-17|2012-11-28|3M创新有限公司|Silicone gel adhesive construction|

WO2010129689A1|2009-05-05|2010-11-11|Forest Laboratories Holdings Limited|Milnacipran formulations|

WO2011073362A1|2009-12-18|2011-06-23|Novartis Ag|Process for the preparation of optically active compounds using pressure hydrogenation|

US10076502B2|2009-12-22|2018-09-18|Luye Pharma Ag|Transdermal therapeutic system for administering rivastigmine or derivatives thereof|

ES2670227T3|2009-12-22|2018-05-29|Luye Pharma Ag|Transdermal therapeutic system for the administration of rivastigmine or its derivatives|

US20100178307A1|2010-01-13|2010-07-15|Jianye Wen|Transdermal anti-dementia active agent formulations and methods for using the same|

RU2578971C2|2010-06-17|2016-03-27|Лтс Ломанн Терапи-Системе Аг|Transdermal administration of memantine|

DE102010024105A1|2010-06-17|2011-12-22|Grünenthal GmbH|Transdermal administration of memantine|

DE102010026903A1|2010-07-12|2012-01-12|Amw Gmbh|Transdermal therapeutic system with avocado oil or palm oil as adjuvant|

JP2013537526A|2010-07-21|2013-10-03|スリーエムイノベイティブプロパティズカンパニー|Transdermal adhesive composition, device, and method|

US8822663B2|2010-08-06|2014-09-02|Moderna Therapeutics, Inc.|Engineered nucleic acids and methods of use thereof|

US20120046383A1|2010-08-19|2012-02-23|Terumo Kabushiki Kaisha|Silicone rubber composition|

EP2625189B1|2010-10-01|2018-06-27|ModernaTX, Inc.|Engineered nucleic acids and methods of use thereof|

KR101788802B1|2010-12-24|2017-10-20|주식회사 삼양바이오팜|Percutaneous absorption preparation containing rivastigmine|

KR101054317B1|2011-01-28|2011-08-08|신신제약 주식회사|Transepidermal drug delivery system containing rivastigmine|

KR101317158B1|2011-02-18|2013-10-15|조선대학교산학협력단|Transdermal drug delivery system comprising galantamine or its salt|

WO2012135805A2|2011-03-31|2012-10-04|modeRNA Therapeutics|Delivery and formulation of engineered nucleic acids|

EP2711002A4|2011-05-20|2014-10-29|Sk Chemicals Co Ltd|Patch containing rivastigmine|

KR20120130073A|2011-05-20|2012-11-28|에스케이케미칼주식회사|Patch comprising rivastigmine|

JP6102739B2|2011-08-31|2017-03-29|東洋インキＳｃホールディングス株式会社|Patch|

US9464124B2|2011-09-12|2016-10-11|Moderna Therapeutics, Inc.|Engineered nucleic acids and methods of use thereof|

CN110511939A|2011-10-03|2019-11-29|现代泰克斯公司|Nucleosides, nucleotide and nucleic acid of modification and application thereof|

AU2012352180A1|2011-12-16|2014-07-31|Moderna Therapeutics, Inc.|Modified nucleoside, nucleotide, and nucleic acid compositions|

US10537581B2|2012-12-21|2020-01-21|Therapeuticsmd, Inc.|Vaginal inserted estradiol pharmaceutical compositions and methods|

US10806740B2|2012-06-18|2020-10-20|Therapeuticsmd, Inc.|Natural combination hormone replacement formulations and therapies|

US20130338122A1|2012-06-18|2013-12-19|Therapeuticsmd, Inc.|Transdermal hormone replacement therapies|

MX365818B|2011-11-23|2019-05-30|Therapeuticsmd Inc|Natural combination hormone replacement formulations and therapies.|

US9301920B2|2012-06-18|2016-04-05|Therapeuticsmd, Inc.|Natural combination hormone replacement formulations and therapies|

US9283287B2|2012-04-02|2016-03-15|Moderna Therapeutics, Inc.|Modified polynucleotides for the production of nuclear proteins|

KR101399035B1|2011-12-22|2014-05-28|주식회사 트랜스덤|Percutaneous absorption preparations containing rivastigmine|

DE102012000369A1|2012-01-11|2013-07-11|Alfred E. Tiefenbacher |Transdermal therapeutic system with cholinesterase inhibitor|

US20150196640A1|2012-06-18|2015-07-16|Therapeuticsmd, Inc.|Progesterone formulations having a desirable pk profile|

US8871245B2|2012-02-28|2014-10-28|Nichiban Co., Ltd.|Transdermal patch|

WO2013142339A1|2012-03-23|2013-09-26|Novartis Ag|Transdermal therapeutic system and method|

AU2013243955B2|2012-04-02|2018-02-22|Modernatx, Inc.|Modified polynucleotides for the production of oncology-related proteins and peptides|

US9878056B2|2012-04-02|2018-01-30|Modernatx, Inc.|Modified polynucleotides for the production of cosmetic proteins and peptides|

US9572897B2|2012-04-02|2017-02-21|Modernatx, Inc.|Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins|

US20150051559A1|2012-04-05|2015-02-19|Sparsha Pharma International Private Limited|Transdermal patch for treatment of dementia or alzheimer type dementia|

WO2013187451A1|2012-06-12|2013-12-19|株式会社ケイ・エムトランスダーム|Patch|

US20160206568A1|2013-06-12|2016-07-21|KM Transderm Ltd.|Adhesive sheet for application to the skin, and percutaneous absorption preparation using same|

US10471072B2|2012-12-21|2019-11-12|Therapeuticsmd, Inc.|Vaginal inserted estradiol pharmaceutical compositions and methods|

US11246875B2|2012-12-21|2022-02-15|Therapeuticsmd, Inc.|Vaginal inserted estradiol pharmaceutical compositions and methods|

US10568891B2|2012-12-21|2020-02-25|Therapeuticsmd, Inc.|Vaginal inserted estradiol pharmaceutical compositions and methods|

US10806697B2|2012-12-21|2020-10-20|Therapeuticsmd, Inc.|Vaginal inserted estradiol pharmaceutical compositions and methods|

US11266661B2|2012-12-21|2022-03-08|Therapeuticsmd, Inc.|Vaginal inserted estradiol pharmaceutical compositions and methods|

CN104582693A|2012-08-15|2015-04-29|道康宁公司|Multi-layer transdermal drug delivery system|

EP2893927A4|2012-09-03|2016-03-09|Nipro Patch Co Ltd|Adhesive skin patch|

KR20140038237A|2012-09-20|2014-03-28|에스케이케미칼주식회사|Medical product showing improved stability of rivastigmine|

US20140083878A1|2012-09-21|2014-03-27|Mylan Inc.|Transdermal drug delivery device|

US9895320B2|2012-09-28|2018-02-20|KM Transderm Ltd.|Transdermal patch with different viscosity hydrocarbon oils in the drug layer and the adhesive layer|

TW201431570A|2012-11-22|2014-08-16|Ucb Pharma Gmbh|Multi-day patch for the transdermal administration of rotigotine|

EP2922554B1|2012-11-26|2022-02-23|ModernaTX, Inc.|Terminally modified rna|

US9180091B2|2012-12-21|2015-11-10|Therapeuticsmd, Inc.|Soluble estradiol capsule for vaginal insertion|

WO2014111790A2|2013-01-15|2014-07-24|Zydus Technologies Limited|Stable transdermal pharmaceutical drug delivery system comprising rivastigmine|

RU2560668C2|2013-03-04|2015-08-20|Общество с ограниченной ответственностью Научно-производственное объединение "Клеточные технологии"|Transdermal sedative pharmaceutical gel for treatment of psychoemotional disorders|

US8980864B2|2013-03-15|2015-03-17|Moderna Therapeutics, Inc.|Compositions and methods of altering cholesterol levels|

AR095259A1|2013-03-15|2015-09-30|Noven Pharma|COMPOSITIONS AND METHODS FOR THE TRANSDERMAL ADMINISTRATION OF TERTIARY AMINE DRUGS|

CA2906796A1|2013-03-15|2014-09-25|Nal Pharmaceuticals Ltd.|Transdermal drug delivery system containing rivastigmine|

GB201309654D0|2013-05-30|2013-07-17|Euro Celtique Sa|Method|

JP6726096B2|2013-07-03|2020-07-22|エルテーエスローマンテラピー−システメアーゲー|Transdermal therapeutic system with electronic components|

US10323076B2|2013-10-03|2019-06-18|Modernatx, Inc.|Polynucleotides encoding low density lipoprotein receptor|

ES2856189T3|2013-10-07|2021-09-27|Teikoku Pharma Usa Inc|Methods and compositions for the treatment of attention deficit hyperactivity disorder, anxiety and insomnia using transdermal compositions of dexmedetomidine|

ES2856748T3|2013-10-07|2021-09-28|Teikoku Pharma Usa Inc|Dexmedetomidine transdermal delivery devices and methods for their use|

EP3081211A4|2013-12-12|2017-10-11|Hisamitsu Pharmaceutical Co., Inc.|Patch with cover member and patch kit with cover member|

CN103877063A|2014-03-24|2014-06-25|张绪伟|Rivastigmine hydrogen tartrate capsule and preparation method thereof|

WO2015156990A1|2014-04-08|2015-10-15|Teikoku Pharma Usa, Inc.|Rivastigmine transdermal compositions and methods of using the same|

JP2017516768A|2014-05-22|2017-06-22|セラピューティックスエムディーインコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ，Ｉｎｃ．|Natural combination hormone replacement therapy and therapy|

CN104523656A|2014-11-20|2015-04-22|美吉斯制药（厦门）有限公司|Rivastigmine sustained-release transdermal patch and preparation method thereof|

DE102015107743A1|2015-05-18|2016-11-24|Bsn Medical Gmbh|Silicone gel coated adhesive layer structure|

US10328087B2|2015-07-23|2019-06-25|Therapeuticsmd, Inc.|Formulations for solubilizing hormones|

US10286077B2|2016-04-01|2019-05-14|Therapeuticsmd, Inc.|Steroid hormone compositions in medium chain oils|

EP3435977A4|2016-04-01|2019-10-16|Therapeuticsmd, Inc.|Steroid hormone pharmaceutical composition|

CN109640976A|2016-08-22|2019-04-16|救急药品工业株式会社|Adhesive preparation|

JP2020503381A|2016-12-20|2020-01-30|エルテーエスローマンテラピー−ジステーメアーゲー|Transdermal therapeutic system containing asenapine|

KR102033686B1|2017-05-19|2019-10-18|보령제약 주식회사|Microneedle transdermal patch comprising donepezil|

CN111093639A|2017-09-05|2020-05-01|罗曼治疗系统股份公司|Transdermal therapeutic system for transdermal administration of rivastigmine|

EP3764996A1|2018-03-13|2021-01-20|LTS Lohmann Therapie-Systeme AG|Transdermal therapeutic system comprising a silicone acrylic hybrid polymer|

BR112020018290A2|2018-03-13|2020-12-29|Lts Lohmann Therapie-Systeme Ag|TRANSDERMAL THERAPEUTIC SYSTEM UNDERSTANDING A HYBRID SILICON AND ACRYLIC POLYMER|

CN111971032A|2018-03-13|2020-11-20|罗曼治疗系统股份公司|Transdermal therapeutic system comprising silicone acrylic hybrid polymers|

BR112020024923A2|2018-06-19|2021-03-09|Lts Lohmann Therapie-Systeme Ag|TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING RIVASTIGMIN|

KR20210113308A|2019-01-31|2021-09-15|히사미쓰 세이야꾸 가부시키가이샤|patch|

法律状态:
2017-11-24| UUP| Utility model expired|Expiry date: 20161010 |

优先权:

申请号 | 申请日 | 专利标题

US74151105P| true| 2005-12-01|2005-12-01|

[返回顶部]